HLB and
Elevar Therapeutics (Elevar) announced on the 26th that they have signed Mark
Gelder, M.D. as Vice President of Medical Affairs at Elevar for fast global
clinical trials and market launches.
Dr. Gelder
majored in Internal Medicine and Obstetrics and Gynecology at the University of
Virginia School of Medicine and published many research papers, particularly as
a clinical trial researcher in the field of gynecological cancer. Since then,
he has been working with Pfizer, Wyeth, and Bayer as Medical Affairs for 17
years, participating in the development of anticancer drugs and leading the
approval and release of various products. Dr. Gelder will lead Elevar's global
clinical organization and lead the overall management and development strategy on
the market and clinical trials of Rivoceranib and Apealea.
“Dr. Gelder is a person who has demonstrated excellent leadership
based on various experiences at global pharmaceutical companies,” said Alex
Kim, CEO of Elevar, “With his consolidation, Elevar's new drug
commercialization capacity will be strengthened and commercialization is
expected to proceed rapidly.”